Limits...
Challenging issues in molecular-targeted therapy.

Ezziane Z - Ther Clin Risk Manag (2009)

Bottom Line: There are variety of anticancer treatments including chemotherapeutic drugs, which are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton toxicity.Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activity through chromatin remodeling and gene expression modulation that affect the cell cycle and survival pathways.This paper proposes an anticancer three-drug compound and discusses several challenging issues in relation to designing multidrug compounds that could possibly lead to molecular-targeted therapies.

View Article: PubMed Central - PubMed

Affiliation: Applied Science and Technology, Higher Colleges of Technology, Al Ain, United Arab Emirates.

ABSTRACT
There are variety of anticancer treatments including chemotherapeutic drugs, which are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton toxicity. Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activity through chromatin remodeling and gene expression modulation that affect the cell cycle and survival pathways. This paper proposes an anticancer three-drug compound and discusses several challenging issues in relation to designing multidrug compounds that could possibly lead to molecular-targeted therapies.

No MeSH data available.


Related in: MedlinePlus

Complex receptor-ligand: Delta-Ex3 (a Survivin isoform) and XY2 (an HRas ligand). This complex has been properly visualized using CheVi (R) (a Linux-based Chemical Visualizer), where XY2 ligand is shown docked along Delta-Ex3’s surface and deeply embedded in a particular active site.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2697511&req=5

f2-tcrm-5-0239: Complex receptor-ligand: Delta-Ex3 (a Survivin isoform) and XY2 (an HRas ligand). This complex has been properly visualized using CheVi (R) (a Linux-based Chemical Visualizer), where XY2 ligand is shown docked along Delta-Ex3’s surface and deeply embedded in a particular active site.

Mentions: The number of events, which occur during the process of killing cancer cells through the combination of two cytotoxic agents, is unknown. Evaluating synergism or antagonism and the explanation of how or why it happens represents different issues.30 Using the latest technological tools, it is possible to design the primary, secondary, and tertiary structure of an enzyme or a receptor as depicted in Figure 2,8 however, it is still hard to design an inhibitor for the drug development process. In addition, the prediction of synergism or antagonism for enzymes or receptors is even more complex.


Challenging issues in molecular-targeted therapy.

Ezziane Z - Ther Clin Risk Manag (2009)

Complex receptor-ligand: Delta-Ex3 (a Survivin isoform) and XY2 (an HRas ligand). This complex has been properly visualized using CheVi (R) (a Linux-based Chemical Visualizer), where XY2 ligand is shown docked along Delta-Ex3’s surface and deeply embedded in a particular active site.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2697511&req=5

f2-tcrm-5-0239: Complex receptor-ligand: Delta-Ex3 (a Survivin isoform) and XY2 (an HRas ligand). This complex has been properly visualized using CheVi (R) (a Linux-based Chemical Visualizer), where XY2 ligand is shown docked along Delta-Ex3’s surface and deeply embedded in a particular active site.
Mentions: The number of events, which occur during the process of killing cancer cells through the combination of two cytotoxic agents, is unknown. Evaluating synergism or antagonism and the explanation of how or why it happens represents different issues.30 Using the latest technological tools, it is possible to design the primary, secondary, and tertiary structure of an enzyme or a receptor as depicted in Figure 2,8 however, it is still hard to design an inhibitor for the drug development process. In addition, the prediction of synergism or antagonism for enzymes or receptors is even more complex.

Bottom Line: There are variety of anticancer treatments including chemotherapeutic drugs, which are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton toxicity.Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activity through chromatin remodeling and gene expression modulation that affect the cell cycle and survival pathways.This paper proposes an anticancer three-drug compound and discusses several challenging issues in relation to designing multidrug compounds that could possibly lead to molecular-targeted therapies.

View Article: PubMed Central - PubMed

Affiliation: Applied Science and Technology, Higher Colleges of Technology, Al Ain, United Arab Emirates.

ABSTRACT
There are variety of anticancer treatments including chemotherapeutic drugs, which are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton toxicity. Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activity through chromatin remodeling and gene expression modulation that affect the cell cycle and survival pathways. This paper proposes an anticancer three-drug compound and discusses several challenging issues in relation to designing multidrug compounds that could possibly lead to molecular-targeted therapies.

No MeSH data available.


Related in: MedlinePlus